Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

(2021) Nancy Y Lee et al.   LANCET ONCOLOGY

Tumor Immunology and Tumor Evolution: Intertwined Histories

(2020) Jérôme Galon et al.   IMMUNITY

CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection

(2020) Erik Wennerberg et al.   Cancer Immunology Research

Concurrent definitive immunoradiotherapy for patients with Stage III-IV Head and Neck Cancer and Cisplatin contraindication

(2020) Jared Weiss et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study

(2020) Steven F. Powell et al.   JOURNAL OF CLINICAL ONCOLOGY

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) David G. Pfister et al.   Journal of the National Comprehensive Cancer Network

Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide

(2020) Ayman J. Oweida et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer

(2020) Xuguang Yang et al.   Cancer Immunology Research

High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors

(2020) Lin Lin et al.   CLINICAL CANCER RESEARCH

The role of regulatory T cells in the response to radiation therapy in head and neck cancer

(2019) Ayman J Oweida et al.   JNCI-Journal of the National Cancer Institute

Radioimmunotherapy for the treatment of head and neck cancer

(2019) Sana D Karam et al.   LANCET ONCOLOGY

Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

(2019) Lei Wu et al.   Cancer Immunology Research

Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer

(2019) Stephanie O. Dudzinski et al.   Journal for ImmunoTherapy of Cancer

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

(2019) Jared M. Newton et al.   Journal for ImmunoTherapy of Cancer

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4

(2019) Zhiyong Wang et al.   Nature Communications

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Myeloid-derived suppressor cells coming of age

(2018) Filippo Veglia et al.   NATURE IMMUNOLOGY

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy

(2018) Padmini Jayaraman et al.   OncoImmunology

Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma

(2018) Sophie Poty et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma

(2017) Cong-Fa Huang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Radiotherapy and immunotherapy: a beneficial liaison?

(2017) Ralph R. Weichselbaum et al.   Nature Reviews Clinical Oncology

Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma

(2017) Ayman Oweida et al.   OncoImmunology

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation

(2017) Megan Morisada et al.   OncoImmunology

Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

(2016) Edward W. Roberts et al.   CANCER CELL

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

(2016) Michael B. Bernstein et al.   Nature Reviews Clinical Oncology

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma

(2016) Yuta Kondo et al.   ORAL ONCOLOGY

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

(2015) Claire Vanpouille-Box et al.   CANCER RESEARCH

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner

(2015) N Werthmöller et al.   Cell Death & Disease

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

(2014) Encouse B Golden et al.   OncoImmunology

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

(2013) J. Xu et al.   CANCER RESEARCH

Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling

(2013) A Ko et al.   CELL DEATH AND DIFFERENTIATION

Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer

(2013) Jian L. Campian et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Immunogenic cell death in radiation therapy

(2013) Lorenzo Galluzzi et al.   OncoImmunology

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH